Pfizer Sues To Block Generic Caduet Until 2016
In a move that could stop Ranbaxy Laboratories Ltd. from marketing a generic version of the hybrid blood pressure and cholesterol drug Caduet until 2016, Pfizer Inc. lodged a declaratory judgment...To view the full article, register now.
Already a subscriber? Click here to view full article